No Data
April 1st [Today's Investment Strategy]
[Fisco Selected Stocks]【Material Stocks】Star Mica Holdings <2975> 920 yen (3/31) engages in the revival and distribution business of used condominiums. The first-quarter financial results have been announced. The operating profit is 2.306 billion yen (an increase of 86.4% compared to the previous year). The renovation condominium business has actively purchased properties, resulting in an increase in Shareholding units. Additionally, in terms of sales, the diversification of exit strategies for owner change properties has been effective. The operating profit for the fiscal year ending November 2025 is projected to be 6.298 billion yen (an increase of 14.0% compared to the previous term).
Strong performance, with an upward trend in the Dow Inc average leading to dominance in buying on dips.
[Emerging Markets Individual Stocks Global Strategy] Today's Emerging Markets are expected to show a stable development. On March 31, the US Stocks market saw the Dow Inc rise by 417.86 points (+1.00%) to 42,001.76, rebounding for the first time in four days. Caution over Trump's tariffs and the diminishing expectations of a ceasefire between Russia and Ukraine weighed on stock prices. On the other hand, the unexpected rise in the Chicago Purchasing Managers' Index and the month-end and quarter-end 'dressing buys' supported the market. Today's Emerging Markets are favorable for Buy.
FanPep, Kids Bio, and others.
The forecast for this period's operating profit has been revised down to 0.39 billion yen from 1.619 billion yen.
FunPep: Confirmation
FunPep: Financial Report - 12th Term (2024/01/01 - 2024/12/31)
Fanpep - Clinical trials for the skin ulcer treatment drug and pollen allergy Vaccine will Start in 2025.
FanPep Co., Ltd. <4881> is a biotech venture established in 2013 with the aim of commercializing research成果 on functional peptides from the Graduate School of Medicine at Osaka Universities. Through independently developed antibody-inducing peptide technology based on functional peptides, the company is working on the development of pharmaceuticals that can serve as alternatives to expensive antibody Pharmaceuticals. Furthermore, in October 2022, it became a subsidiary of Anti-Aging Peptides Co., Ltd. (currently FanPep Healthcare), expanding into non-pharmaceuticals such as Cosmetics.